Treatment of recurrent glioblastoma: Can local delivery of mitoxantrone improve survival?

Journal of Neuro-Oncology

Volumn 88, Issue 1, 2008, Pages 105-113

  Boiardi, Amerigo ^a   Silvani, Antonio ^a   Eoli, Marica ^a   Lamperti, Elena ^a   Salmaggi, Andrea ^a   Gaviani, Paola ^a   Fiumani, Anna ^a   Botturi, Andrea ^a   Falcone, Chiara ^a   Solari, Alessandra ^a   Filippini, Graziella ^a   Meco, Francesco ^a   Broggi, Giovanni ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Glioblastoma; Locoregional chemotherapy; Mitoxantrone; Ommaya reservoir; Rickam reservoir

Indexed keywords

ANTICONVULSIVE AGENT; CARMUSTINE; CISPLATIN; DEXAMETHASONE; MITOXANTRONE; TEMOZOLOMIDE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN RADIATION; BRAIN SURGERY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SURVIVOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DECUBITUS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HAZARD RATIO; HUMAN; INJECTION SITE BLEEDING; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHOTON THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; REOPERATION; RETROSPECTIVE STUDY; RISK REDUCTION; SEIZURE; SKIN ABSCESS; SKIN INFECTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THERAPY EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGING; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SURVIVAL; TREATMENT OUTCOME;

EID: 42349107740     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9540-6     Document Type: Article

References (48)

1. Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1327
2. Fine HA, Dear KBG, Loeffler YS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597
3. Tatter SB (2002) Recurrent malignant glioma in adults. Curr Treat Options Oncol 3:509-524
4. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
5. Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
6. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
7. Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytoma; results of a systematic review of 1415 patients. Anticancer Res 18:1303-1312
8. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593
9. Brada M, Hoang-Xuan K, Rampling R et al (2002) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:149-150
10. Dillman RO, Duma CM, Schiltz PM et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27:398-404
11. Lidar Z, Mardor Y, Jonas T et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100:472-479
12. Chan TA, Weingart JD, Parisi M (2005) Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133-1139
13. Di Meco F, Li KW, Tyler BM et al (2002) Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 5:1173-1178
14. Brem H, Piantadossi S, Burger P et al (1995) Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008-1012
15. Westphal M, Ram Z, Riddle V et al (2006) On behalf of the executive committee of the Gliadel study group. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269-275
16. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79-88
17. Senkal M, Tonn JC, Schonmayr R et al (1997) Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J Neurooncol 32:203-208
18. Perego P, Boiardi A, Carenini N et al (1994) Characterisation of an established human malignant glioblastoma cell line and its response to conventional drugs. J Cancer Res Clin Oncol 120:585-592
19. Nikkhah G, Tonn JC, Hoffmann O (1992) The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: evaluation of patient- and drug-specific variables. J Neurooncol 13:13-24
20. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: A meta analysis. J Cancer Res Clin Oncol 125:481-486
21. Ferroli P, Broggi M, Franzini A et al (2006) Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: The first step of locoregional chemotherapy through an ad hoc-placed catheter: Technical note. Neurosurgery 59:433-434
22. Boiardi A, Eoli M, Salmaggi A et al (2005) A systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. J Neurooncol 75:215-220
23. Boiardi A, Eoli M, Salmaggi A et al (2003) New approach in delivering chemotherapy: Locoregional treatment for recurrent glioblastoma (rGBM). J Exp Clin Cancer Res 22:123-127
24. MacDonald DR, Cascino TL, Clifford S (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
25. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
26. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649-655
27. Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26:397-409
28. Osoba D, Brada M, Prados MD (2000) Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-Oncology 4:221-228
29. Abrey LE (2005) Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme. Curr Neurol Neurosci Rep 5:167-168
30. Gaya A, Rees J, Greenstein A et al (2002) The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28:115-120
31. Sipos L, Vitanovics D, Afra D (2001) Treatment of recidive malignant gliomas with temozolomide. Ann Oncol 12:259-266
32. Sipos L, Vitanovics D, Afra D (2002) Treatment of recidive malignant gliomas with temozolomide. Orv Hetil 143(21):1201-1204
33. Sipos L, Afra D (1997) Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir (Wien) 139:99-104
34. Hau P, Baumgart U, Pfeifer K et al (2003) Salvage therapy in patients with glioblastoma: Is there any benefit? Cancer 98:2678-2686
35. Soults CB, Canute GS, Ryken TC (1998) Evidence-based review of the role of reoperation in the management of malignant glioma. Neurosurg Focus 15:11-16
36. Guyotat J, Signorelli F, Frappaz D et al (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7:899-904
37. Barker FG, Chang SM, Gutin PH et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709-720
38. Pinsker M, Lumenta C (2001) Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43-47
39. Ammirati M, Galicich JH, Arbit E (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607-614
40. Dirks P, Bernstein M, Muller PJ et al (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36:271-275
41. Gabayan AJ, Green SB, Sanan A et al (2006) GliaSite brachytherapy for treatment of recurrent malignant gliomas: A retrospective multi-institutional analysis. Neurosurgery 59:821-826
42. Combs SE, Thilmann C, Edler L (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863-8869
43. Shrieve DC, Alexander E, Wen PY (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275-282
44. Riva P, Franceschi G, Riva N et al (2000) Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601-609
45. Paganelli G, Bartolomei M, Ferrari M (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227-235
46. Akabani G, Reardon DA, Coleman RE et al (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46:1042-1051
47. Hayes RL, Koslow M, Hiesiger EM (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840-852
48. Lawson HC, Sampath P, Bohan E et al (2007) Interstitial chemotherapy for malignant gliomas: The Johns Hopkins experience. J Neurooncol 83:61-70